India is home to 60% of the total global visceral leishmaniasis (VL) population. Use of long-term oral (e. g. miltefosine) and parenteral drugs, considered the mainstay for treatment of VL, is now faced with increased resistance, decreased efficacy, low compliance and safety issues. The authors evaluated the efficacy and safety of an alternate treatment option, i. e. single infusion of preformed amphotericin B (AmB) lipid emulsion (ABLE) in comparison with that of liposomal formulation (LAmB). In this multicentric, open-label study, 500 patients with VL were randomly assigned in a 3∶1 ratio to receive 15 mg/kg single infusion of either ABLE (N = 376) or LAmB (N = 124). Initial cure (Day 30/45), clinical improvement (Day 30) and long term definitive cure (Day 180) were assessed. A total of 326 (86. 7%) patients in the ABLE group and 122 (98. 4%) patients in the LAmB group completed the study. Initial cure was achieved by 95. 9% of patients in the ABLE group compared to 100% in the LAmB group (p = 0. 028; 95% CI: −0. 0663, −0. 0150). Clinical improvement was comparable between treatments (ABLE: 98. 9% vs. LAmB: 98. 4%). Definitive cure was achieved in 85. 9% with ABLE compared to 98. 4% with LAmB. Infusion-related pyrexia (37. 2% vs. 32. 3%) and chills (18. 4% vs. 18. 5%) were comparable between ABLE and LAmB, respectively. Treatment-related serious adverse events were fewer in ABLE (0. 3%) compared to LAmB (1. 6%). Two deaths occurred in the ABLE group, of which one was probably related to the study drug. Nephrotoxicity and hepatotoxicity was not observed in either group. ABLE 15 mg/kg single infusion had favorable efficacy and was well tolerated. Considering the demographic profile of the population in this region, a single dose treatment offers advantages in terms of compliance, cost and applicability. www. clinicaltrials. gov NCT00876824
Visceral leishmaniasis (VL), also known as kala-azar, is a vector-borne disease transmitted to humans by the bite of an infected sandfly [1]. Globally, around 200,000–400,000 cases of VL occur each year of which 60% cases occur in India alone [2]. Kala-azar is a major public health problem in the areas of its prevalence, principally India and its neighbors Bangladesh and Nepal. In India, the disease is highly prevalent in Bihar, Jharkhand, West Bengal and pockets of eastern Uttar Pradesh. Among these, Bihar is the most affected with >90% of cases [3], of which 10% are fatal [2]. Contrary to the severity, few drugs are available for its treatment and are further limited by safety, reduced effectiveness and challenges in administration. Use of pentavalent antimonials, the mainstay of treatment for over 70 years, has been limited by its resistance and toxicities [4]. In India, almost 65% of previously untreated cases fail to respond promptly or relapse after treatment with antimonials [5]. Efficacy of the first-line oral treatment, miltefosine (MF) has declined rapidly over the past decade (final cure rate: 96. 7% in 1999,94% in 2002,82% in 2007, and 72% in 2011) and is also associated with gastrointestinal side effects [6]–[9]. In addition, owing to its teratogenic effects, treatment with MF may require strict medical monitoring for treating women of child bearing age, which considering current demographic outlook of India is a significant factor [10], [11]. Paramomycin, an aminoglycoside, had shown 94% cure rate but is associated with systemic hepatic toxicity; the current regimen of 21 daily injections is also a major disadvantage for routine clinical use [12]. Amphotericin B (AmB), currently a second line drug used for treatment of VL, is highly effective with cure rates of 97%; however, the administration of 15 intravenous injections (i. v.) over 30 days of hospitalization, coupled with infusion- and drug-related adverse effects [13], has limited its wide-spread use. Liposomal formulations of AmB (LAmB) are better tolerated and thus preferable to conventional AmB [14], [15]. Despite the WHO-negotiated price of LAmB, treatment with it still remains limited and unaffordable in India [16]. Educational, social and economic background of patients in endemic areas entails therapy that does not bother patients with cost, undue compliance issues and long treatment duration, making a simplified treatment regimen a need of the hour. Thus, an affordable premixed AmB deoxycholate with lipid emulsion (ABLE) was developed (licensed in India) [17] and can be a potential candidate for treatment and elimination in endemic countries. Previous Phase II studies have reported safety and efficacy with a single infusion of 15 mg/kg of ABLE [17], [18] in the treatment of VL. This Phase III study was conducted to evaluate the efficacy and safety of ABLE versus LAmB (both 15 mg/kg single dose infusions) in the treatment of VL.
The protocol was approved by an Independent Ethics Committee or Institutional Review Board at each study site and the study was conducted in accordance with the ethical principles originating in the Declaration of Helsinki and in accordance with ICH Good Clinical Practice guidelines, applicable regulatory requirements, and in compliance with the protocol. All participants including guardians in case of minors provided written informed consent to participate in the study. This study was registered at ClinicalTrials. gov (NCT00876824). This was a prospective, multicentric, randomized, open-label, comparative Phase III study. Patients were enrolled from 4 centers in Bihar, India, between August 2009 and January 2011. Male and female, aged 5–65 years (both inclusive) diagnosed with VL (fever >2 weeks duration and splenomegaly), who had amastigotes (Leishmania donovani bodies) at prescreening (detected by recombinant K39 protein [rK39] dipstick test) and confirmed VL by splenic or bone marrow aspirate smear examination were included in the study. Other inclusion criteria were hemoglobin (Hb) ≥5 g/dL, white blood cells count ≥1000/cmm, platelet count ≥50000/cmm, prothrombin time ≤4 seconds above the control, and alkaline transaminase, aspartate transaminase, and alkaline phosphatase ≤2. 5 times the upper limit of normal. Patients with past history of treatment with AmB or any other drug for VL within 30 days prior to screening, major surgery within 2 weeks prior to screening, concurrent malaria, alcoholism or illicit drug use/abuse or any condition associated with poor compliance, hypersensitivity to AmB, inactive ingredients of ABLE and LAmB formulations were excluded from the study. Patients who received any of the prohibited medications (any other investigational drugs, antileishmanial drugs other than study drug, corticosteroids, skeletal muscle relaxants, cyclosporine, digoxin, vancomycin, aminoglycosides, antifungal, immunosuppresive agents, and all potentially nephrotoxic drugs), who were positive for human immunodeficiency virus, hepatitis C virus and hepatitis B surface antigen infections and immune-compromised, were also excluded from the study. Eligible patients were randomized (3∶1) to receive either ABLE or LAmB, as 15 mg/kg single dose infusions (Figure 1). Prior to administration of full-dose, patients received initial test doses (ABLE and LAmB) of 1 mg in 5% dextrose as an infusion over ∼15–20 minutes for the ABLE treatment and over a period of 10 minutes for the LAmB treatment. Patients who experience any hypersensitivity or cardiopulmonary complications of hypersensitivity were withdrawn from the study. Full dose of ABLE and LAmB was diluted in 5% dextrose to a concentration of 1 mg/ml prior to administration. Patients received full doses of respective treatment in single intravenous infusion over 4–6 hours. Premedication was not allowed prior to the study drug administration. Patients were hospitalized for 7 days starting from day of first dose of the study drug for safety and efficacy evaluation. To assess parasitological cure, splenic aspirate (or bone marrow aspirate in whom splenic aspirates was not feasible) was performed on Day 30 post infusion. Parasite density was graded by microscopy using a conventional logarithmic scale of 0 (no amastigotes/1000 oil-immersion fields) to +6 (>100 amastigotes/1000 oil-immersion field). Patients with +1 score on Day 30 were re-evaluated on Day 45. Patients were considered to achieve initial cure if the score was 0 on either Day 30 or 45. Patients with score >+1 on Day 30 and/or ≥1 on Day 45 were considered as treatment failures. They were withdrawn from the study and treated with rescue medication in appropriate doses as indicated in the protocol (LAmB 5 mg/kg i. v. on Days 1,3, 5 and 7 or alternative antileishmanial drug in appropriate doses). Patients were further observed for clinical improvement presented as absence of fever and one or more of the following: increase in Hb concentration by ≥10%, weight gain, or decrease in spleen size by ≥33% (compared from baseline to Day 30). Patients who had achieved initial cure were followed-up for 6 months to study any sign/symptoms of relapse of VL. Patients with an initial cure and no signs or symptoms of VL at the last visit were considered to have achieved definitive cure. All the patients were monitored for incidence of infusion related toxicities, nephrotoxicity, hepatotoxicity, number of adverse events (AEs), treatment-emergent AEs (TEAEs), serious AEs (SAEs), and laboratory values (normal; abnormal, not clinically significant; and abnormal, clinically significant) for different parameters. Any drug related Grade III or higher AEs recorded for abnormal clinically significant renal function tests or liver function tests were classified as nephrotoxicity or hepatotoxicity as per National Cancer Institute Common Terminology Criteria (NCI-CTC) AE, version 3. A total of 500 patients in a 3∶1 ratio (375 in ABLE and 125 in LAmB) were planned to be enrolled assuming a dropout rate of 20% and non-inferiority margin fixed at −0. 10. This was expected to provide an estimated difference in proportions of patients achieving definitive cure for ABLE vs. LAmB equals to zero, with at least 80% power for the non-inferiority test. The permuted block randomization, with block size of 4, and ratio of 3∶1 in the two groups (ABLE and LAmB) were generated for each center. Eligible patients were sequentially allotted to unique subject ID and treatment (ABLE or LAmB) as per randomization schedule for that center. The screening and randomization log was maintained. Data were expressed as means (±SD) for continuous variables and percentages for categorical variables. Proportion of patients achieving all three-efficacy (initial cure, clinical improvement and definitive cure) endpoints were to be compared across the two treatment groups. For initial cure and clinical improvement, the data was to be analyzed using chi-square test at 5% level of significance. But as the expected number of patients achieving or non achieving initial cure in any of the treatment group was found to be <5, a Fisher' s exact test was used. P-value<0. 05 was considered as statistically significant. For definitive cure, non-inferiority was assessed by looking at the lower end of a two-sided 95% confidence interval (CI) of the difference Ptest - Pref (the difference in the proportions of patients achieving definitive cure in ABLE (Ptest) and LAmB (Pref). Non-inferiority was only accepted if the lower limit of the two-sided 95% CI was greater than the non-inferiority margin of −0. 10. For the three efficacy parameters, the 95% CI was calculated by using Wald' s confidence interval with Yate' s continuity correction formula. For safety, the number and percentage of patients experiencing toxicities and AEs (including laboratory abnormalities) across two treatment groups were summarized. Percentages were based on total number of patients in ITT population in each treatment groups. The efficacy analysis was performed on modified intent-to-treat (mITT) population, which includes all patients who received study drug as per the protocol specified duration and had at least one efficacy assessment throughout the study. Safety analysis was performed on intent-to-treat (ITT) population, which includes all patients who received the treatment of study drug.
Of the 500 patients randomized, 376 patients received ABLE and 124 patients received LAmB. The percentage of patients who completed the study was lower in the ABLE group (86. 7%) compared with the LAmB group (98. 4%). A total of 50 (13. 3%) patients discontinued the study in the ABLE group compared to 2 patients (1. 6%) in the LAmB group (Figure 2). Patients were predominantly men (60. 8%); mean age was 24. 8 years (range: 5 to 62 years), and the rest of the baseline characteristics were similar for both groups (Table 1). In this study, all patients were qualified for treatment and included in the ITT population. The proportion of patients with at least 1 AE was comparable in both the ABLE group and in the LAmB group (202 [53. 7%] and 61 [49. 2%]) (Table 3). The majority of AEs considered to be possibly related to the study drug was similar in both treatment groups (45. 2%). Similarly, TEAEs in the ABLE (179 [47. 6%]) and LAmB (56 [45. 2%]) were comparable. The most common TEAEs in both ABLE and LAmB were chills (18. 4% and 18. 5%) and pyrexia (37. 2% and 32. 3%), respectively (Table 3). The majority (>35%) of the patients (152 [40. 4%] vs. 46 [37. 1%]) experienced AEs of mild intensity. Two patients in each group had at least one SAE (ABLE 0. 5% vs. LAmB 1. 6%). Of these SAEs, one patient (0. 3%) in the ABLE and 2 (1. 6%) patients in the LAmB group was considered treatment-related. The SAEs that occurred in ABLE were anemia, diarrhea, vomiting and sudden death; while in LAmB, pancytopenia and diarrhea (in one patient each). In total, two deaths occurred in the ABLE group due to AEs. One death occurred 2 days after drug administration due to severe diarrhea and was considered probably related to the drug. The other death occurred on Day 157 and was not related to the study drug. In the LAmB group, one patient (0. 8%) was discontinued from the study due to urticaria (Table 3). The incidence of infusion related toxicities on Day 1 was comparable between the groups (43. 6% in ABLE and 41. 9% in LAmB group). None of the patients in both the treatment groups had signs and symptoms of nephrotoxicity and hepatotoxicity.
In this study, ABLE 15 mg/kg single bolus was found to be efficacious, safe and well tolerated in patients with VL. In addition, its ancillary properties such as favorable applicability and compliance (due to single dose administration), low cost and unrestricted supply, make it a suitable option for VL treatment in endemic countries.
Visceral leishmaniasis (VL) is highly prevalent in northeastern India, particularly the state of Bihar and its bordering areas with Bangladesh and Nepal. The current standards of treatment, namely, miltefosine (oral) and pentavalent antimonials (parenteral) have long treatment durations and are faced with increasing resistance, decreased efficacy, low compliance and safety issues. In this regard, lipid formulations of amphotericin B (AmB) have become an attractive treatment option due to their high efficacy, shorter treatment regimens and favorable safety profiles. This Phase III study evaluated the efficacy and safety of preformed AmB lipid emulsion (ABLE) versus liposomal AmB (LAmB) (both 15 mg/kg single dose infusions) in the treatment of VL. ABLE showed favorable efficacy measured in terms of initial cure at Day 30/45, and overall clinical improvement. ABLE was well tolerated and its adverse event profile was consistent with previously documented findings. Based on the favorable efficacy and safety profile of ABLE, and considering the demographic profile of the population in the endemic region, a single dose treatment may offer advantages in terms of compliance, cost and applicability.
phase iii clinical investigation
medicine and health sciences
clinical medicine
clinical trials
randomized controlled trials
Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral Leishmaniasis: A Randomized, Open-Label Study